Home > Newsletters > FDAnews Drug Daily Bulletin > FDA Issues 48 Product-Specific Bioequivalence Guidances
FDAnews Drug Daily Bulletin
Oct. 2, 2012 | Vol. 9 No. 193
FDA Issues 48 Product-Specific Bioequivalence Guidances
The FDA has issued dozens of draft and revised draft product-specific guidances that detail its recommendations for bioequivalence (BE) studies to support ANDAs. New draft product-specific BE recommendations are available for 32 drug products. Drugs with the active ingredients amoxicillin, budesonide, linagliptin, omeprazole and paclitaxel are just a few of those listed in the FDA’s Sept. 14 Federal Register notice.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.